Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)
Immune checkpoint inhibitors (ICIs) are novel anticancer agents, recently introduced with the aim of boosting the immune response against tumors. ICIs are monoclonal autoantibodies that specifically target inhibitory receptors on T cells: cytotoxic T lymphocyte antigen 4 (CTLA4), programmed death 1 (PD-1) and its ligand (PD-1L). ICIs also generate peculiar dysimmune toxicities, called immune-related adverse events (irAEs), that can potentially affect any tissue, and some may be life-threatening if not promptly recognized. The endocrine and metabolic side effects of ICIs are reviewed here, with a particular focus on their clinical presentation and management. They are among the most frequent toxicities (around 10%) and include hypophysitis, thyroid disorders, adrenalitis, and diabetes mellitus. Treatment is based on the replacement of specific hormone deficits, accompanied by immunosuppression (with corticosteroids or other drugs), depending on irAEs grade, often without the need of ICI withdrawal, except in more severe forms. Prompt recognition of endocrine and metabolic irAEs and adequate treatment allow the patients to continue a therapy they are benefiting from. Endocrinologists, as an integral part of the multidisciplinary oncologic team, need to be familiar with the unique toxicity profile of these anticancer agents. Practical recommendations for their management are proposed.
KeywordsImmune checkpoint inhibitors Cancer treatment Endocrine side effects CTLA4 PD1/PD1-L Thyroid diseases Hypophysitis Hyponatremia
This research did not receive any specific Grant from any funding agency in the public, commercial or not-for-profit sector.
Compliance with ethical standards
Conflict of interest
The authors declare they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent is not required.
- 8.Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Society for Immunotherapy of Cancer Toxicity Management Working Group et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https://doi.org/10.1186/s40425-017-0300-z CrossRefPubMedPubMedCentralGoogle Scholar
- 12.US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda, Md, 2010. [updated (v4.03: June 14, 2010) May 28, 2009]. NIH publication no. 90-5410Google Scholar
- 14.Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193–3198CrossRefGoogle Scholar
- 15.Herbst RS, Baas P, Kim D, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRefGoogle Scholar
- 20.Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, MDX010-20 Investigators (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675–1682CrossRefGoogle Scholar
- 22.Guaraldi F, La Selva R, Samà MT, D’Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41:549–556. https://doi.org/10.1007/s40618-017-0772-1 CrossRefPubMedGoogle Scholar
- 28.Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C et al (2005) Cytotoxic T lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593–598CrossRefGoogle Scholar
- 31.Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 19:372(26)Google Scholar
- 35.Giuffrida G, Campennì A, Trimarchi F, Ruggeri RM (2017) Thyroid dysfunction in patients treated with the immune checkpoint inhibitor nivolumab: different clinical features. APMB 105(2):A2 (1–6). https://doi.org/10.6092/1828-6550/apmb.105.2.2017.a2 CrossRefGoogle Scholar
- 42.Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E, Hyponatraemia Guideline Development Group (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 170:G1–47. https://doi.org/10.1530/EJE-13-1020 CrossRefPubMedGoogle Scholar
- 43.Howard SA, Krajewski KM, Jagannathan JP, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Ramaiya NH (2016) A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. Am J Roentgenol 207:4–14. https://doi.org/10.2214/AJR.15.15480 CrossRefGoogle Scholar
- 49.Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y et al (2016) Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 5:1204–1507CrossRefGoogle Scholar
- 50.Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR (2013) Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune- related gastrointestinal adverse events. J Transl Med 11:75CrossRefGoogle Scholar
- 52.Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ, Society for Endocrinology Clinical Committee (2018) Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7:G1–G7. https://doi.org/10.1530/ec-18-0068 CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, Guidelines Committee ESMO (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142. https://doi.org/10.1093/annonc/mdx225 CrossRefPubMedGoogle Scholar